Genomed Spólka Akcyjna provides DNA and RNA sequencing and analysis and diagnostics services for congenital diseases in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company's diagnostic services include DNA isolation, PCR amplification of chosen DNA regions, comparison of the sequences, and interpretation of the results by diagnosticians. It also provides various types of DNA sequence analysis, including polymorphism analysis or sequencing of phage genetic material or bacteria genomes; and next-generation sequencing and genetic counseling services. In addition, the company offers DNA oligonucleotides synthesis, RNA oligonucleotides and peptide synthesis, various nucleotide modifications, and the 4LAB automated pipetting workstation, as well as laboratory equipment through e-store. It serves scientific institutes, universities, hospitals, and biotechnological and pharmaceutical companies, as well as healthcare networks and individual customers. The company was founded in 2007 and is headquartered in Warsaw, Poland.
Research context
GEN appears in PyInvesting’s Warsaw Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- PLN
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
No comments yet
Start a focused discussion about GEN.WAR.